MedTrace Logo

AGN-229666 for the Treatment of Allergic Conjunctivitis

NCT01754766 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2014-02-04

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AGN-229666

One drop of AGN-229666 into each eye on Day 1 and Day 15.

OTHER

vehicle of AGN-229666

One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01754766 on ClinicalTrials.gov